Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial

Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial

BackgroundHepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) has poor prognosis. Sorafenib/lenvatinib is recommended as the first-line therapy in these patients currently, with unsatisfactory response and survival benefit reported. Radiotherapy (RT) is increasingly util...

Full description

Bibliographic Details
Main Authors: Yue Hu, Tingting Qin, Shuang Li, Tao Zhang, Jun Xue
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
HCC
PVTT
SBRT
camrelizumab
apatinib
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01589/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01589/full

Similar Items